Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...
New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...
Boston Scientific and Abbott this week both put forward separate studies supporting their respective implants for sealing off the heart’s left atrial appendage—the pocket within the cardiac muscle ...
On Saturday, Boston Scientific Corporation (NYSE:BSX) unveiled three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device ...
(Updated) SAN FRANCISCO, California — Preliminary data from the PREVAIL study of the Watchman (AtriTech/Boston Scientific) device for the prevention of stroke and systemic embolism in patients with ...
A Central New York man is sharing his story after decades of heart issues, and how a small device is helping protect his life ...
17 deaths and 120 serious injuries have been reported due to complications during Watchman procedures. Boston Scientific warned Watchman customers of a higher risk of complications during procedures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results